Comunicato stampa: HAS Healthcare Advanced Synthesis Earns the Esteemed 2024 AITI Award During its 40th Anniversary Celebration
HAS Healthcare Advanced Synthesis the prestigious 2024 AITI Award in recognition of its forty years of outward focus on high-quality technological innovation, conscientious sustainable and ethical approach, as well as an unwavering determination to fulfill its clients’ requirements.
Biasca, Switzerland, April 11th, 2024
HAS Healthcare Advanced Synthesis SA (“HAS”), a full-service contract development and manufacturing organization (CDMO) delivering high-quality, exclusive, personalized solutions to its healthcare clients, is delighted to announce that it has been honored with the 2024 AITI Award.
This recognition acknowledges HAS’s 40 years of outstanding achievements and unwavering focus on delivering cutting-edge customized solutions to its healthcare clients, and in turn, on helping patients worldwide enjoy a better quality of life.
It also stands as evidence of the collective effort and commitment from our entire workforce.
Since our inception in 1984, family owned HAS offers the best CDMO standards by delivering active pharmaceutical ingredients (APIs), highly potent active pharmaceutical ingredients (HPAPIs), and anticancer compounds to pharmaceutical and biotechnology companies. Our quality focus and commitment to satisfying customer expectations, along with a strong dedication to prioritizing sustainability and ethical practices, thereby creating positive impacts on both our community and our planet, have been the cornerstone of our success, propelling us to the forefront of the global pharmaceutical industry.
We are proud to share this achievement with our stakeholders as we continue to innovate and strive for excellence.
Dr. Waldo Mossi, PhD, CEO, HAS Healthcare Advanced Synthesis, commented: “As we celebrate our achievements, our unwavering focus remains on the future. We will persistently drive progress, foster partnerships, and create value for our clients and patients across the globe.”
About HAS
HAS Healthcare Advanced Synthesis is a CDMO that offers a full range of customized services from laboratory development to manufacturing. HAS Healthcare Advanced Synthesis develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, high-activity active pharmaceutical ingredients (HPAPIs) and anticancer compounds.
The production facility is located in Biasca, Switzerland, and was founded in 1984.
The site is regularly inspected by SwissMedic, the FDA and other global regulatory agencies. The production scale ranges from a few hundred grams to tens of kilograms for highly active ingredients (HPAPI) and anticancer and from kilograms to tens of tons for standard active ingredients (APIs); the plants are completely dedicated to cGMP production.
Contact Press Office
HAS Healthcare Advanced Synthesis
Biasca, Switzerland
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: email hidden; JavaScript is required
